Tissue-specific contributions of pneumococcal virulence factors to pathogenesis

Journal of Infectious Diseases

Volumn 190, Issue 9, 2004, Pages 1661-1669

  Orihuela, Carlos J ^a   Gao, Geli ^a   Francis, Kevin P ^b   Yu, Jun ^b   Tuomanen, Elaine I ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Xenogen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLYSIN; MEMBRANE PROTEIN; PYRUVATE OXIDASE; SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BACTERIAL VIRULENCE; BIOLUMINESCENCE; CEREBROSPINAL FLUID; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE CASSETTE; LOWER RESPIRATORY TRACT; LUNG INFECTION; MENINGIOMA; MOUSE; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTEREMIA; BACTERIAL PROTEINS; CEREBROSPINAL FLUID; DISEASE MODELS, ANIMAL; FEMALE; LUNG; MENINGITIS, PNEUMOCOCCAL; MICE; MICE, INBRED BALB C; MUTATION; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; NASOPHARYNX; NEURAMINIDASE; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; PYRUVATE OXIDASE; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; VIRULENCE FACTORS;

EID: 6944224035     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/424596     Document Type: Article

References (42)

1. Musher D. Streptococcus pneumoniae. In: Dolin R, ed. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia: Churchill Livingston, 2000:2128-46.
2. Mandell LA. Community-acquired pneumonia: etiology, epidemiology, and treatment. Chest 1995; 108:S35-42.
3. Bohr V, Paulson OB, Rasmussen N. Pneumococcal meningitis: late neurologic sequelae and features of prognostic impact. Arch Neurol 1984; 41:1045-9.
4. Robinson DA, Briles DE, Crain MJ, Hollingshead SK. Evolution and virulence of serogroup 6 pneumococci on a global scale. J Bacteriol 2002; 184:6367-75.
5. Rossi A, Corso A, Pace J, Regueira M, Tomasz A. Penicillin-resistant Streptococcus pneumoniae in Argentina: frequent occurrence of an internationally spread serotype 14 clone. Microb Drug Resist 1998; 4:225-31.
6. Lacks S, Hotchkiss RD. A study of the genetic material determining an enzyme activity in the pneumococcus. Biochim Biophys Acta 1960; 39:508-17.
7. Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of the pneumococcal types: induction of transformation by the deoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 1944; 79:137-57.
8. Francis KP, Yu J, Bellinger-Kawahara C, et al. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon. Infect Immun 2001; 69:3350-8.
9. Zhang JR, Mostov KE, Lamm ME, et al. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell 2000; 102:827-37.
10. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 1989; 57:2037-42.
11. Spellerberg B, Cundell DR, Sandros J, et al. Pyruvate oxidase, as a determinant of virulence in Streptococcus pneumoniae. Mol Microbiol 1996; 19:803-13.
12. Briles DE, Yother J, McDaniel LS. Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Infect Dis 1988; 10(Suppl 2):S372-4.
13. Orihuela CJ, Gao G, McGee M, Yu J, Francis KP, Tuomanen EI. Organ-specific models of Streptococcus pneumoniae disease. Scand J Infect Dis 2003; 35:647-52.
14. Tettelin H, Nelson KE, Paulsen IT, et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 2001; 293:498-506.
15. Majewski J, Zawadzki P, Pickerill P, Cohan FM, Dowson CG. Barriers to genetic exchange between bacterial species: Streptococcus pneumoniae transformation. J Bacteriol 2000; 182:1016-23.
16. Gosink KK, Mann ER, Guglielmo C, Tuomanen EI, Masure HR. Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. Infect Immun 2000; 68:5690-5.
17. Rubins JB, Charboneau D, Fasching C, et al. Distinct roles for pneumolysin's cytotoxic and complement activities in the pathogenesis of pneumococcal pneumonia. Am J Respir Crit Care Med 1996; 153:1339-46.
18. Rosenow C, Ryan P, Weiser JN, et al. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 1997; 25:819-29.
19. Lock RA, Paton JC, Hansman D. Purification and immunological characterization of neuraminidase produced by Streptococcus pneumoniae. Microb Pathog 1988; 4:33-43.
20. Ring A, Tuomanen E. Host cell invasion by Streptococcus pneumoniae. Subcell Biochem 2000; 33:125-35.
21. Balachandran P, Hollingshead SK, Paton JC, Briles DE. The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol 2001; 183:3108-16.
22. Berry AM, Lock RA, Hansman D, Paton JC. Contribution of autolysin to virulence of Streptococcus pneumoniae. Infect Immun 1989; 57:2324-30.
23. Berry AM, Paton JC. Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun 2000; 68:133-40.
24. Berry AM, Ogunniyi AD, Miller DC, Paton JC. Comparative virulence of Streptococcus pneumoniae strains with insertion-duplication, point, and deletion mutations in the pneumolysin gene. Infect Immun 1999; 67:981-5.
25. Rubins JB, Duane PG, Charboneau D, Janoff EN. Toxicity of pneumolysin to pulmonary endothelial cells in vitro. Infect Immun 1992; 60:1740-6.
26. Nandoskar M, Ferrante A, Bates EJ, Hurst N, Paton JC. Inhibition of human monocyte respiratory burst, degranulation, phospholipid methylation and bactericidal activity by pneumolysin. Immunology 1986; 59:515-20.
27. Pericone CD, Overweg K, Hermans PW, Weiser JN. Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect Immun 2000; 68:3990-7.
28. Howard LV, Gooder H. Specificity of the autolysin of Streptococcus (Diplococcus) pneumoniae. J Bacteriol 1974; 117:796-804.
29. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002; 15:95-110.
30. Schroder NW, Morath S, Alexander C, et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003; 278:15587-94.
31. Cauwels A, Wan E, Leismann M, Tuomanen E. Coexistence of CD14-dependent and independent pathways for stimulation of human monocytes by gram-positive bacteria. Infect Immun 1997; 65:3255-60.
32. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999; 163:1-5.
33. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev 2001; 65:187-207; first page, table of contents.
34. Howie AJ, Brown G. Effect of neuraminidase on the expression of the 3-fucosyl-N-acetyllactosamine antigen in human tissues. J Clin Pathol 1985; 38:409-16.
35. Tong HH, Blue LE, James MA, DeMaria TF. Evaluation of the virulence of a Streptococcus pneumonias neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model. Infect Immun 2000; 68:921-4.
36. Tong HH, Liu X, Chen Y, James M, Demaria T. Effect of neuraminidase on receptor-mediated adherence of Streptococcus pneumoniae to chinchilla tracheal epithelium. Acta Otolaryngol 2002; 122:413-9.
37. Hava DL, Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol 2002; 45:1389-106.
38. Ren B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 2003; 71:75-85.
39. Yamamoto M, McDaniel LS, Kawabata K, et al. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun 1997; 65:640-4.
40. McDaniel LS, Yother J, Vijayakumar M, McGarry L, Guild WR, Briles DE. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 1987; 165:381-94.
41. Abeyta M, Hardy GG, Yother J. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun 2003; 71:218-25.
42. Briles DE, Hollingshead SK, Paton JC, et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 2003; 188:339-48.